Cargando…

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer

SIMPLE SUMMARY: Breast cancer diagnosis at the initial stage of the disease considerably improves prognosis and survival rates. This retrospective study aimed to develop and validate a plasma microRNA signature as a non-invasive biomarker for early-stage breast cancer diagnosis. We confirmed in a te...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adam-Artigues, Anna, Garrido-Cano, Iris, Carbonell-Asins, Juan Antonio, Lameirinhas, Ana, Simón, Soraya, Ortega-Morillo, Belén, Martínez, María Teresa, Hernando, Cristina, Constâncio, Vera, Burgues, Octavio, Bermejo, Begoña, Henrique, Rui, Lluch, Ana, Jerónimo, Carmen, Eroles, Pilar, Cejalvo, Juan Miguel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201361/ https://www.ncbi.nlm.nih.gov/pubmed/34200463 http://dx.doi.org/10.3390/cancers13112848

Ejemplares similares

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer
por: Garrido-Cano, Iris, et al.
Publicado: (2020)

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer
por: Adam-Artigues, A., et al.
Publicado: (2021)

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective
por: Hernando, Cristina, et al.
Publicado: (2021)

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
por: Garrido-Cano, Iris, et al.
Publicado: (2023)

MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma
por: Pattanayak, Birlipta, et al.
Publicado: (2020)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies
por: Garrido‐Cano, Iris, et al.
Publicado: (2022)

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
por: Oltra, Sara S., et al.
Publicado: (2020)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2023)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
por: Tormo, Eduardo, et al.
Publicado: (2019)

Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator
por: Martínez, María Teresa, et al.
Publicado: (2019)

MicroRNAs as a clue to overcome breast cancer treatment resistance
por: Garrido-Cano, Iris, et al.
Publicado: (2021)

Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway
por: Pattanayak, Birlipta, et al.
Publicado: (2022)

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
por: Pineda, Begoña, et al.
Publicado: (2019)

MicroRNA profile in very young women with breast cancer
por: Peña-Chilet, Maria, et al.
Publicado: (2014)

Identification of Candidate Polymorphisms on Stress Oxidative and DNA Damage Repair Genes Related with Clinical Outcome in Breast Cancer Patients
por: Rodrigues, Patricia, et al.
Publicado: (2012)

Associations between Aromatase CYP19 rs10046 Polymorphism and Breast Cancer Risk: From a Case-Control to a Meta-Analysis of 20,098 Subjects
por: Pineda, Begoña, et al.
Publicado: (2013)

Acceleration in the DNA methylation age in breast cancer tumours from very young women
por: Oltra, Sara S., et al.
Publicado: (2019)

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
por: Tormo, Eduardo, et al.
Publicado: (2017)

miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker
por: Oltra, Sara S, et al.
Publicado: (2020)

The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2016)

Methylation deregulation of miRNA promoters identifies miR124-2 as a survival biomarker in Breast Cancer in very young women
por: Oltra, Sara S., et al.
Publicado: (2018)

Receptor Activator of Nuclear Factor Kappa B (RANK) and Clinicopathological Variables in Endometrial Cancer: A Study at Protein and Gene Level
por: Gómez, Raúl, et al.
Publicado: (2018)

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma
por: Rojo, Federico, et al.
Publicado: (2016)

Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2018)

The Complex Interplay between Metabolic Reprogramming and Epigenetic Alterations in Renal Cell Carcinoma
por: Lameirinhas, Ana, et al.
Publicado: (2019)

Corrigendum: Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
por: Miranda-Gonçalves, Vera, et al.
Publicado: (2019)

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver
por: Hruschka, Natascha, et al.
Publicado: (2020)

Pain sensitivity in patients with schizophrenia: a systematic review and meta-analysis
por: Juan P, Carrasco-Picazo, et al.
Publicado: (2023)

Determination of somatic oncogenic mutations linked to target-based therapies using MassARRAY technology
por: Ibarrola-Villava, Maider, et al.
Publicado: (2016)

Clinical Significance of ARID1A and ANXA1 in HER-2 Positive Breast Cancer
por: Silva-Oliveira, Rita, et al.
Publicado: (2020)

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis
por: Jimenez Rodriguez, Begona, et al.
Publicado: (2019)

Histological Grade and Tumor Stage Are Correlated with Expression of Receptor Activator of Nuclear Factor Kappa b (Rank) in Epithelial Ovarian Cancers
por: Gomez, Raul, et al.
Publicado: (2022)

Development of a Novel NGS Methodology for Ultrasensitive Circulating Tumor DNA Detection as a Tool for Early-Stage Breast Cancer Diagnosis
por: Jiménez-Rodríguez, Begoña, et al.
Publicado: (2022)

Opioid Receptor Expression in Colorectal Cancer: A Nested Matched Case-Control Study
por: Belltall, Amparo, et al.
Publicado: (2022)

Aurora kinases in ovarian cancer
por: Pérez-Fidalgo, J Alejandro, et al.
Publicado: (2020)

Detection of SARS-CoV-2 RNA in Urine by RT-LAMP: A Very Rare Finding
por: García-Bernalt Diego, Juan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_pkatsmkm1tnov23i4v332cjbpq